Health in Flemington, NJ

About 12 years ago LHNC was forged in response to an urgency for helping communities create lasting change toward health. Two of my colleagues chose to begin this project on Fort Peck reservation in Montana because the suicide rate among the children there was the highest in our nation. Sinc...

Achieve any physical skill with this method: gmb.io/method/ Getting physical skills doesn't have to be complicated. We've distilled thousands of hour...

You can pick up a printed gift certificate in the office OR we can email you a digital one. Either way, just reach out and let us know who you are giving this gift to so that we can prepare for your loved one
These gift certificates will be honored from December 2018 through March 2019.
Office Cell Phone
Please note: We are dropping the office cell phone number and will no longer be accepting text messaging appointments.
Please call the office at…

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S.

Are You Ready to Sculpture the buttock and belly with Emsculpt?
Are you Ready to Sculpture the Buttock and Belly with Emsculpt?

Isn’t it maddening when you eat right and exercise regularly, but still have specific areas you can’t get the fat to disappear from? No matter how hard you try, it doesn’t seem to make any difference how many miles you...

Such a great time and discussion of EMsculpt and other various procedures!
We have one very lucky patient that won one EMsculpt treatment !
Call for a complimentary consultation with regard to EMsculpt.

KENILWORTH, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced detailed results from the Phase 3 SOLO-1 trial testing LYNPARZA 300 mg tablets twice daily as a maintenance treatment for patients with newly-diagnosed advanced BRCA-mutated (BRCAm) ovarian cancer who were in comp

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA® (pembrolizumab), Mer

A Culinary Affair, which benefits Hunterdon Hospice and Visiting Health and Supportive Services, will be held on September 24 from 6-9 p.m. at the Grand Colonial in Lebanon.

Hunterdon Healthcare System (HHS), one of New Jersey’s leading independent not-for-profit health systems has retained Witt/Kieffer to support their efforts to recruit an authentic, progressiv